Merck: EU agency backs Keytruda as lung cancer drug
(CercleFinance.com) - European regulators recommended the approval of Merck's new cancer drug Keytruda in combination with chemotherapy for the treatment of metastatic non-small cell lung cancer.
More specifically, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Merck's anti-PD-1 therapy in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumors have no EGFR or ALK genomic tumor aberrations, regardless of PD-L1 expression.
Lung cancer is the leading cause of death from cancer in both Europe and worldwide.
The CHMP also adopted a positive opinion recommending approval of Keytruda as monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma, Merck said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
More specifically, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Merck's anti-PD-1 therapy in combination with pemetrexed and platinum chemotherapy for the first-line treatment of metastatic non-squamous non-small cell lung cancer (NSCLC) in adults whose tumors have no EGFR or ALK genomic tumor aberrations, regardless of PD-L1 expression.
Lung cancer is the leading cause of death from cancer in both Europe and worldwide.
The CHMP also adopted a positive opinion recommending approval of Keytruda as monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma, Merck said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.